8-K - ILLUMINA, INC. (0001110803) (Filer)

8-K - ILLUMINA, INC. (0001110803) (Filer)

8-K - ILLUMINA, INC. (0001110803) (Filer)

8-K - ILLUMINA, INC. (0001110803) (Filer)

FWP - ILLUMINA, INC. (0001110803) (Subject)

S-3ASR - ILLUMINA, INC. (0001110803) (Filer)

10-Q - ILLUMINA, INC. (0001110803) (Filer)

8-K - ILLUMINA, INC. (0001110803) (Filer)

8-K - ILLUMINA, INC. (0001110803) (Filer)

8-K - ILLUMINA, INC. (0001110803) (Filer)

SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, announced updates to its agreement with Illumina Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies. Myriad's gold-standard Genomic Instability Score (GIS) to determine Homologous Recombination Deficiency (HRD) will be reported for all samples analyzed with Illumina's updated research assay, TruSight™ Oncology 500 v2 (TSO 500 v2). Previously, GIS to determine HRD was only available as a separate product. As a result, a broad array of cancer types will receive GIS results and their HRD status. "We are pleased to expand o

The latest solution to enable comprehensive genomic profiling of tumors will be presented at the annual meeting of the Association of Molecular Pathology Customer-led research and presentations at the conference will deliver the latest evidence and education in tumor profiling SAN DIEGO, Nov. 19, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will release TruSight™ Oncology 500 v2 (TSO 500 v2), a new version of its flagship cancer research assay to enable comprehensive genomic profiling (CGP). The assay is currently under development, with global release planned for mid-2025. Detailed plans for the pr

SAN DIEGO, Nov. 6, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conferences: Wolfe Research 2024 Healthcare Conference on November 20, 2024Fireside chat at 6:20am Pacific Time (9:20am Eastern Time)7th Annual Evercore HealthCONx Conference on December 3, 2024Fireside chat at 10:20am Pacific Time (1:20pm Eastern Time)For each conference, the webcast can be accessed through the Investor Info section of Illumina's website at investor.illumina.com. A replay will be posted on Illumina's website after

Core Illumina revenue of $1.1 billion for Q3 2024, down 2% from Q3 2023 and on a constant currency basisCore Illumina GAAP operating margin of 68.6% and non-GAAP operating margin of 22.6% for Q3 2024Core Illumina GAAP diluted EPS of $4.03 and non-GAAP diluted EPS of $1.14 for Q3 2024Lowered fiscal year 2024 Core Illumina revenue guidance to decline ~3% from fiscal year 2023; expect Q4 2024 Core Illumina revenue of approximately $1.07 billionRaised fiscal year 2024 Core Illumina non-GAAP operating margin guidance to a range of 21% to 21.5%Raised fiscal year 2024 Core Illumina non-GAAP diluted EPS guidance to a range of $4.05 to $4.15SAN DIEGO, Nov. 4, 2024 /PRNewswire/ -- Illumina, Inc. (NASD

New, groundbreaking technology delivers Illumina's most comprehensive genome yet; early results from Broad Clinical Labs demonstrate a highly simplified workflow, ultra-long phasing, high-resolution insights into complex genomic variation, and enhanced long-range information  Illumina and customers will also showcase new details on complete proteomics solution and latest data on Fluent single-cell technologySAN DIEGO, Oct. 31, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will present updates on several key innovations in whole-genome sequencing, proteomics, and single-cell technology at the American

Designed to make next-generation sequencing accessible to more labs With room-temperature kit storage and shipping, Illumina's newest sequencers remove barriers to enable more insights and discoveries SAN DIEGO, Oct. 9, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, today unveiled its MiSeq™ i100 Series of sequencing systems, delivering unparalleled benchtop speed and simplicity to advance next-generation sequencing (NGS) for labs. The two new benchtop instruments, MiSeq i100 and MiSeq i100 Plus Systems, will empower customers to unlock powerful insights through an affordable, comprehensive solu

SAN DIEGO, Oct. 7, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the third quarter 2024 following the close of market on Monday, November 4, 2024.  On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.  Conference Call Details The conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Monday, November 4, 2024. Interested parties may access the live teleconference through the Investor Info section

SAN DIEGO, Oct. 3, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, announced that after 11 years of service, Charles "Chuck" Dadswell will step down as General Counsel and Secretary on October 3. Dadswell has agreed to remain an Illumina employee, serving as an advisor to CEO Jacob Thaysen and the Board of Directors, through March 31, 2025. Scott Davies has been named acting General Counsel and Secretary while the company conducts a search for Dadswell's permanent successor. Dadswell joined the company as General Counsel in 2013, following a distinguished career providing legal counsel to the biotechnology sector. Most recen

SAN DIEGO, Sept. 3, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, welcomes the European Court of Justice's (ECJ's) judgment today ruling that the European Commission did not have jurisdiction over Illumina's acquisition of GRAIL. Today's judgment confirms Illumina's longstanding view that the European Commission exceeded its authority by asserting jurisdiction over this merger. The basis for the 432 million euro fine has now been removed and will no longer be payable. Following Illumina's spin-off of GRAIL in June 2024, GRAIL is now an independent public company. Illumina maintains a minority share of 14.5% in GRAIL, and I

Data Support Clinical Performance of Galleri to Detect More Aggressive Prostate Cancers MENLO PARK, Calif., Aug. 29, 2024 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL) a healthcare company whose mission is to detect cancer early when it can be cured, today announced that detailed findings of the performance of its Galleri® multi-cancer early detection (MCED) test in prostate cancer were published in JCO Precision Oncology. The data support the clinical performance of the Galleri test to preferentially screen for aggressive, clinically significant prostate cancer as compared to slow-growing (indolent) cases in the Circulating Cell-free Genome Atlas (CCGA) and PATHFINDER studies.

4 - ILLUMINA, INC. (0001110803) (Issuer)

4 - ILLUMINA, INC. (0001110803) (Issuer)

4 - ILLUMINA, INC. (0001110803) (Issuer)

4 - ILLUMINA, INC. (0001110803) (Issuer)

4 - ILLUMINA, INC. (0001110803) (Issuer)

4 - ILLUMINA, INC. (0001110803) (Issuer)

3 - ILLUMINA, INC. (0001110803) (Issuer)

4 - ILLUMINA, INC. (0001110803) (Issuer)

4 - ILLUMINA, INC. (0001110803) (Issuer)

4 - ILLUMINA, INC. (0001110803) (Issuer)

4 - ILLUMINA, INC. (0001110803) (Issuer)

Core Illumina revenue of $1.1 billion for Q3 2024, down 2% from Q3 2023 and on a constant currency basisCore Illumina GAAP operating margin of 68.6% and non-GAAP operating margin of 22.6% for Q3 2024Core Illumina GAAP diluted EPS of $4.03 and non-GAAP diluted EPS of $1.14 for Q3 2024Lowered fiscal year 2024 Core Illumina revenue guidance to decline ~3% from fiscal year 2023; expect Q4 2024 Core Illumina revenue of approximately $1.07 billionRaised fiscal year 2024 Core Illumina non-GAAP operating margin guidance to a range of 21% to 21.5%Raised fiscal year 2024 Core Illumina non-GAAP diluted EPS guidance to a range of $4.05 to $4.15SAN DIEGO, Nov. 4, 2024 /PRNewswire/ -- Illumina, Inc. (NASD

SAN DIEGO, Oct. 7, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the third quarter 2024 following the close of market on Monday, November 4, 2024.  On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.  Conference Call Details The conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Monday, November 4, 2024. Interested parties may access the live teleconference through the Investor Info section

Core Illumina revenue of $1.09 billion for Q2 2024, down 6% from Q2 2023 (down 6% on a constant currency basis) and up 3% from Q1 2024Core Illumina GAAP operating margin of 40.5% and non-GAAP operating margin of 22.2% for Q2 2024Core Illumina GAAP diluted earnings per share of $0.41 and non-GAAP diluted earnings per share of $1.09 for Q2 2024Lowered fiscal year 2024 Core Illumina revenue guidance to decline 2% to 3% (down 1.5% to 2.5% in constant currency) from 2023Raised Core Illumina non-GAAP operating margin guidance to a range of 20.5% to 21% for fiscal year 2024Introducing guidance for Core Illumina non-GAAP diluted earnings per share in the range of $3.80 to $3.95 for fiscal year 2024O

SAN DIEGO, July 11, 2024 /PRNewswire/ -- As Illumina, Inc. (NASDAQ:ILMN) previously announced on June 24, the company will issue results for the second quarter 2024 following the close of market on Tuesday, August 6, 2024.  On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.  Conference Call Details The conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Tuesday, August 6, 2024. Interested parties may access the live teleconference through the Inv

 Accessible, highly scalable single-cell technology expands Illumina's multiomics capabilities SAN DIEGO, July 9, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, announced that effective today it has acquired Fluent BioSciences, developer of an emerging and highly differentiated single-cell technology.   "The addition of Fluent BioSciences to Illumina will provide significant and new capabilities to our customers in a key growth area and advances our multiomics growth strategy," said Steven Barnard, chief techn

"When-issued" trading expected to begin on or about June 12, 2024Record date for distribution of GRAIL shares will be June 13, 2024Distribution date for GRAIL shares anticipated to be June 24, 2024SAN DIEGO, June 3, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced that its Board of Directors has approved the spin-off of GRAIL. GRAIL is anticipated to spin off from Illumina on June 24, 2024, and has applied to list on Nasdaq as "GRAL." "Today's announcement marks a milestone for Illumina and signals an important step forward for the company, since the divestiture of GRAIL is one of our 2024 priorities," said Jacob Thaysen, CEO of Illumina. "As we prepare to lead the next era

Core Illumina revenue of $1.06 billion for Q1 2024, down 2% from Q1 2023 (down 2% on a constant currency basis)Core Illumina GAAP operating margin of 11.0% and non-GAAP operating margin of 20.6% for Q1 2024Reiterating fiscal year 2024 Core Illumina revenue guidance that is approximately flat compared to 2023 and a Core Illumina non-GAAP operating margin for fiscal year 2024 of approximately 20%Consolidated revenue of $1.08 billion for Q1 2024, down 1% from Q1 2023 (down 1% on a constant currency basis)GAAP diluted loss per share of ($0.79) for Q1 2024, compared to GAAP diluted earnings per share of $0.02 for Q1 2023Non-GAAP diluted earnings per share of $0.09 for Q1 2024, compared to non-GAA

SAN DIEGO, April 4, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the first quarter 2024 following the close of market on Thursday, May 2, 2024.  On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Jacob Thaysen, Chief Executive Officer, and Joydeep Goswami, Chief Financial Officer and Chief Strategy and Corporate Development Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.  Conference Call Details The conference call will begin at 2:00 pm Pacific Time (5:00 pm Eastern Time) on Thursday, May 2, 2024. Interested parties may access the live tele

Revenue of $1.12 billion for Q4 2023, up 4% from Q4 2022 (up 4% on a constant currency basis)Revenue of $4.50 billion for fiscal year 2023, down 2% from fiscal year 2022 (flat on a constant currency basis)Shipped 79 NovaSeq X instruments in Q4 2023 and 352 instruments for fiscal year 2023GAAP diluted loss per share of $(1.11) for Q4 2023, compared to GAAP diluted loss per share of $(0.89) for Q4 2022Non-GAAP diluted earnings per share of $0.14 for both Q4 2023 and Q4 2022GAAP diluted loss per share of $(7.34) for fiscal year 2023, which included goodwill and intangible impairments of $821 million related to the GRAIL segment, compared to GAAP diluted loss per share of $(28.00) for fiscal yea

SAN DIEGO, Jan. 4, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the fourth quarter and full year 2023 following the close of market on Thursday, February 8, 2024.  On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Jacob Thaysen, Chief Executive Officer, and Joydeep Goswami, Chief Financial Officer and Chief Strategy and Corporate Development Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call Details The conference call will begin at 2:00 pm Pacific Time (5:00 pm Eastern Time) on Thursday, February 8, 2024. Interested parties

NEW YORK, June 7, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from the S

Cunningham previously served as CCO for Exact Sciences and brings more than 20 years of commercial leadership across healthcare tech, life sciences, and pharma  SAN DIEGO, June 3, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the appointment of Everett Cunningham as Chief Commercial Officer (CCO), effective June 10.    Cunningham will be responsible for building, guiding, and managing the company's global commercial organization. He brings extensive commercial experience across the healthcare

Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Mostafa Ronaghi, PhD, has been appointed to its Board of Directors, effective immediately. "We are excited to add Dr. Ronaghi to complement our excellent group of current board members," stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit. "Mostafa has valuable experience in translating innovative concepts in genomics and sequencing that ultimately lead to advancements in patient care through his work at Illumina, Grail, and his continuing ventures. As we intend to maximize the potential of ivonescimab, we are excited to add the acumen and expertise that Mostafa can bring to

Joydeep Goswami to serve as advisor through June 30 Illumina reaffirms Q1 2024 and full-year 2024 financial guidance SAN DIEGO, April 9, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that Joydeep Goswami has decided to leave Illumina. He will stay on in an advisory role through June 30 to support two new executive management team appointments. Ankur Dhingra is joining Illumina as Chief Financial Officer (CFO), leading Illumina's financial planning and analysis, accounting, investor relations,

The companies plan to join forces to set up pathogen monitoring programs utilizing Illumina technology across Concentric's global network  BOSTON and SAN DIEGO, Jan. 15, 2024 /PRNewswire/ -- Concentric by Ginkgo, the biosecurity and public health unit of Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced that it has entered into a Co-Marketing Agreement with Illumina, Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, to partner on expanding biosecurity capabilities globally.

Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4

SAN DIEGO, Sept. 5, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, today announced that its Board of Directors has appointed Jacob Thaysen, Ph.D., senior vice president of Agilent Technologies and president of its Life Sciences and Applied Markets Group, as Chief Executive Officer, effective September 25, 2023. Mr. Thaysen's extensive background and experience in genomics, life sciences, and technology fits closely with Illumina's mission. Since 2018, he has overseen the unit responsible for Agilent's market-l

SAN DIEGO, June 11, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, today announced that its Board of Directors has accepted the resignation of Francis deSouza as Illumina's Chief Executive Officer and as a Director, effective Sunday, June 11. Charles Dadswell, Senior Vice President and General Counsel, has been named interim CEO while the Board of Directors conducts a search for a new CEO. Mr. deSouza will stay on in an advisory capacity until July 31, 2023. Illumina's Board said it is appreciative of Mr. deSouza's contributions and commitment to the company and all of its stakeholders. "We thank Francis for his contributions

Board Chair John Thompson issues letter to Illumina shareholders ahead of the company's Annual Meeting on May 25, 2023, at 10:00 am Pacific Time (1:00 pm Eastern Time)Illumina requests shareholders to vote the WHITE proxy card today FOR all nine of Illumina's director nomineesFor more information, visit www.IlluminaForward.comSAN DIEGO, May 18, 2023 /PRNewswire/ -- Illumina (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, today issued a shareholder letter from Board Chair John Thompson. In his letter, Mr. Thompson reiterated the specific steps the company is taking to deliver results consistent with the high standards of performance and value creation expected b

Illumina's director nominees bring deep commercial, scientific and business experience from leading organizations including Microsoft, Symantec, and Medco-UBCLeading proxy advisory firm ISS has recommended Illumina shareholders vote FOR Illumina CEO Francis deSouza and Board member Robert EpsteinIcahn's associates bring ZERO relevant experience and ZERO independenceIllumina requests shareholders to vote the WHITE proxy card today FOR all nine of Illumina's director nomineesAnnual Meeting will be held virtually on May 25, 2023, at 10:00 am Pacific Time (1:00 pm Eastern Time)For more information, visit www.IlluminaForward.comSAN DIEGO, May 15, 2023 /PRNewswire/ -- Illumina (NASDAQ:ILMN), a glo

Illumina (NASDAQ:ILMN) has outperformed the market over the past 20 years by 12.43% on an annualized basis producing an average annual return of 20.85%. Currently, Illumina has a market capitalization of $18.45 billion. Buying $1000 In ILMN: If an investor had bought $1000 of ILMN stock 20 years ago, it would be worth $46,623.49 today based on a price of $115.79 for ILMN at the time of writing. Illumina's Performance Over Last 20 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine a

Illumina (NASDAQ:ILMN) has outperformed the market over the past 20 years by 12.7% on an annualized basis producing an average annual return of 21.1%. Currently, Illumina has a market capitalization of $18.49 billion. Buying $100 In ILMN: If an investor had bought $100 of ILMN stock 20 years ago, it would be worth $4,729.97 today based on a price of $116.10 for ILMN at the time of writing. Illumina's Performance Over Last 20 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and re

Wednesday, Illumina Inc (NASDAQ:ILMN) acquired Fluent BioSciences to expand its reach in single-cell analysis and multiomics research for an undisclosed consideration. Amid this M&A deal, 10x Genomics, Inc (NASDAQ:TXG) shares are trading lower. William Blair writes that Fluent’s PIPseq single-cell technology does not require an instrument, and costs per cell is at least 50% less than 10x and is the cheapest on the market, citing a recent bioRxiv preprint. William Blair highlights that cost reduction has become crucial in the increasingly crowded single-cell market. Bundled offerings will further strengthen Fluent’s competitive edge with low-cost positioning. While Illumina emphasize

Last month, Illumina Inc (NASDAQ:ILMN) had to let go of Grail Inc. Still, the DNA sequencing company has acquired Fluent BioSciences to expand its reach in single-cell analysis and multiomics research. Launched in 2018, Fluent was backed by Illumina’s venture capital arm. Other investors include Samsara Biocapital, Civilization Ventures, Co-win Ventures and VC23. While the financial details were not disclosed, the company said the deal was closed and funded with cash it had on hand. At the close of the first quarter, the company held $1.115 billion in cash, cash equivalents and short-term investments. Fluent’s single-cell analysis technology eliminates the need for complex, expen

U.S. stocks were mostly higher, with the Nasdaq Composite gaining around 0.4% on Wednesday. Shares of SMART Global Holdings, Inc. (NASDAQ:SGH) rose sharply during Wednesday's session after the company reported better-than-expected third-quarter financial results. SMART Global reported quarterly earnings of 37 cents per share, which beat the analyst consensus estimate of 30 cents. Quarterly sales came in at $300.6 million, which beat the analyst consensus estimate of $300 million, according to data from Benzinga Pro. SMART Global shares jumped 17.4% to $27.27 on Wednesday. Here are some other big stocks recording gains in today’s session. Solaris Oilfield Infrastructure, Inc.

Stephens & Co. analyst Mason Carrico reiterates Illumina (NASDAQ:ILMN) with a Overweight and maintains $170 price target.

Citigroup analyst Patrick Donnelly upgrades Illumina (NASDAQ:ILMN) from Neutral to Buy and announces $140 price target.

In the preceding three months, 10 analysts have released ratings for Illumina (NASDAQ:ILMN), presenting a wide array of perspectives from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 6 3 1 0 Last 30D 0 1 0 0 0 1M Ago 0 1 2 0 0 2M Ago 0 2 1 0 0 3M Ago 0 2 0 1 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $165.1, a high estimate of $253.00, and a low estimate of $100.00. This current averag

Morgan Stanley resumed coverage of Illumina with a rating of Equal-Weight and set a new price target of $156.00

HSBC Securities upgraded Illumina from Hold to Buy and set a new price target of $180.00

Argus upgraded Illumina from Hold to Buy

Daiwa Securities upgraded Illumina from Neutral to Buy and set a new price target of $154.00 from $120.00 previously

TD Cowen upgraded Illumina from Hold to Buy and set a new price target of $144.00 from $126.00 previously

Barclays upgraded Illumina from Underweight to Equal Weight and set a new price target of $125.00

Citigroup upgraded Illumina from Neutral to Buy and set a new price target of $140.00

Jefferies resumed coverage of Illumina with a rating of Hold and set a new price target of $115.00

HSBC Securities downgraded Illumina from Buy to Hold

TD Cowen downgraded Illumina from Outperform to Market Perform and set a new price target of $144.00